Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 25;23(1):91.
doi: 10.1186/s40644-023-00604-4.

Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study

Yongjian Guo #  1   2 , Jingqiang Wu #  1   2 , Licong Liang #  1   2 , Kangshun Zhu  1   2 , Jingwen Zhou  1   2 , Liteng Lin  1   2 , Ye Chen  1   2 , Bihui Cao  1   2 , Mingji He  1   2 , Hui Lian  1   2 , Wensou Huang  3   4 , Mingyue Cai  5   6
Affiliations

Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study

Yongjian Guo et al. Cancer Imaging. .

Abstract

Purpose: To investigate the efficacy and safety of tyrosine-kinase inhibitor (TKI) combined with iodine-125 seed brachytherapy (TKI-I) versus TKI alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).

Methods: Data of patients with TACE-refractory HCC who received TKI (sorafenib or lenvatinib) or TKI-I from September 2018 to December 2020 were retrospectively analyzed. A propensity score matching (PSM) was performed to diminish potential bias. The primary endpoints were overall survival (OS) and time to progression (TTP). Tumor responses and treatment-related adverse events (TRAEs) were also compared between the two groups.

Results: A total of 132 patients were included in this study. Under PSM, 48 paired patients were selected for comparison. The median OS was 23.2 (95% CI 20.9-25.1) months in the TKI-I group versus 13.9 (95% CI 11.1-16.7) months in the TKI group (P < 0.001). The median TTP was 12.8 (95% CI 10.1-15.5) months in the TKI-I group versus 5.8 (95% CI 5.0-6.6) months in the TKI group (P < 0.001). Patients in the TKI-I group had higher objective response rate (68.8% vs. 33.3%, P = 0.001) and disease control rate (89.6% vs. 66.7%, P = 0.007) than those in the TKI group. The incidence and severity of TRAEs in the TKI-I group were comparable to those in the TKI group (any grade, 89.7% vs. 92.2%, P = 0.620; ≥grade 3, 33.8% vs. 32.8%, P = 0.902).

Conclusions: TKI-I was safe and significantly improved survival over TKI alone in HCC patients with TACE refractoriness.

Keywords: Brachytherapy; Combined modality therapy; Hepatocellular carcinoma; Therapeutic chemoembolization; Tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of patient selection. HCC hepatocellular carcinoma, TACE transarterial chemoembolization, TKI-I tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy, TKI tyrosine-kinase inhibitor, HAIC hepatic arterial infusion chemotherapy, PT prothrombin time
Fig. 2
Fig. 2
Kaplan-Meier curves for overall survival in the matched cohort according to treatment modality. TKI-I tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy, TKI tyrosine-kinase inhibitor
Fig. 3
Fig. 3
Kaplan-Meier curves for time to progression of (A) overall tumor, (B) intrahepatic tumor and (C) vascular tumor thrombus in the matched cohort according to treatment modality. TKI-I tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy, TKI tyrosine-kinase inhibitor
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the diagnosis and treatment of Hepatocellular Carcinoma (2019 Edition) Liver Cancer. 2020;9:682–720. doi: 10.1159/000509424. - DOI - PMC - PubMed
    1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894–905. doi: 10.1056/NEJMoa1915745. - DOI - PubMed
    1. Lu J, Zhao M, Arai Y, Zhong BY, Zhu HD, Qi XL, et al. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO) Hepatobiliary Surg Nutr. 2021;10:661–71. doi: 10.21037/hbsn-21-260. - DOI - PMC - PubMed